Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

Translated title of the contribution: Nivolumab + ipilimumab (N + I) vs sunitinib (S) for the first-line treatment of advanced renal cell carcinoma (aRCC) in the CheckMate 214 study: 4-year follow-up and subgroup analysis of non-nephrectomized patients (pts)

L. Albiges, N. Tannir, M. Burotto, D. Mcdermott, E. Plimack, P. Barthélémy, C. Porta, T. Powles, F. Donskov, S. George, C. Kollmannsberger, H. Gurney, M. Grimm, Y. Tomita, D. Castellano, B. Rini, T. Choueiri, S. Shally Saggi, M. Mchenry, R. Motzer

Research output: Contribution to journalMeeting abstractpeer-review

Translated title of the contributionNivolumab + ipilimumab (N + I) vs sunitinib (S) for the first-line treatment of advanced renal cell carcinoma (aRCC) in the CheckMate 214 study: 4-year follow-up and subgroup analysis of non-nephrectomized patients (pts)
Original languageFrench
Article numberCO-150
Pages (from-to)785-786
Number of pages2
JournalProgres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
Volume30
Issue number13
DOIs
Publication statusPublished - 1 Nov 2020
Event114ème Congrès Français d'Urologie - Virtual conference, France
Duration: 18 Nov 202020 Nov 2020

Cite this